The assay will be useful for higher throughput combinatorial sampling of the dominant-negative activity of cancer-associated p53 mutants across diverse panels of response elements, and to investigate how interactions of wild-type/mutant p53 with other p53 family members (p63 and p73)56 impacts DNA binding. Here, TP53 is linked to cancer.